Base de dados : MEDLINE
Pesquisa : C12.294.565.500 [Categoria DeCS]
Referências encontradas : 19186 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1919 ir para página                         

  1 / 19186 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29376615
[Au] Autor:Kamalov AA; Takhirzade AM
[Ad] Endereço:Department of Urology and Andrology, Faculty of Fundamental Medicine, Lomonosov MSU, Moscow, Russia.
[Ti] Título:[Current approaches to conservative treatment of men with concomitant benign prostatic hyperplasia and erectile dysfunction].
[So] Source:Urologiia;(6):160-163, 2017 Dec.
[Is] ISSN:1728-2985
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:The article reviews the results of various conservative treatments for concomitant benign prostatic hyperplasia (BPH) and erectile dysfunction (ED). Phosphodiesterase type 5 (PDE5) inhibitors remain the first-line therapy for this category of patients taking into account their positive effect on both ED and BPH. The preferred treatment scheme includes PDE-5 inhibitor co-administered with 1-adrenoblocker. However, other combination treatments are considered promising, for example, a PDE-5 inhibitor with a 5-reductase inhibitor or a three-component treatment regimen: 1-adrenoblocker + 5-reductase inhibitor + PDE-5 inhibitor. All these approaches to treating patients with BPH and ED have demonstrated high efficiency and safety. Nevertheless, a limited number of randomized clinical trials and short-term observations suggest the need for further studies investigating the long-term outcomes of different treatment options for such patients.
[Mh] Termos MeSH primário: Inibidores de 5-alfa Redutase/uso terapêutico
Antagonistas de Receptores Adrenérgicos alfa 1/uso terapêutico
Disfunção Erétil
Inibidores da Fosfodiesterase 5/uso terapêutico
Hiperplasia Prostática
[Mh] Termos MeSH secundário: Disfunção Erétil/tratamento farmacológico
Disfunção Erétil/etiologia
Disfunção Erétil/patologia
Disfunção Erétil/fisiopatologia
Seres Humanos
Masculino
Hiperplasia Prostática/complicações
Hiperplasia Prostática/tratamento farmacológico
Hiperplasia Prostática/patologia
Hiperplasia Prostática/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (5-alpha Reductase Inhibitors); 0 (Adrenergic alpha-1 Receptor Antagonists); 0 (Phosphodiesterase 5 Inhibitors)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180130
[St] Status:MEDLINE


  2 / 19186 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29376601
[Au] Autor:Orlov IN; Popov SV; Martov AG; Gallyamov EA; Malevich SM; Sushina IV; Grin EA; Sanzharov AE; Novikov AB; Sergeev VP; Kochkin AD
[Ad] Endereço:St. Lukes Clinical Hospital, St. Petersburg, Russia.
[Ti] Título:[Comparative assessment of treatments for prostate adenoma greater than 100 cm3].
[So] Source:Urologiia;(6):82-86, 2017 Dec.
[Is] ISSN:1728-2985
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:AIM: To compare holmium laser enucleation of the prostate (HoLEP) and endovideosurgical (EVS) adenomectomy in the treatment of prostate adenoma. MATERIALS AND METHODS: We compared treatment results of 180 patients with prostate adenomas greater than 100 cm3 who underwent EVS adenomectomy (n=90) and laser enucleation of the prostate (n=90). The analysis included the following parameters: duration of catheterization, length of postoperative hospital stay, I-PSS score, maximum urinary flow rate measured by uroflowmetry and complications according to Clavien-Dindo grading systems. RESULTS: There were no significant differences in patient age, preoperative prostate size, glandular tissue weight, and operative time. The duration of catheterization (p=0.0008) and length of postoperative hospital stay (p<0.0001) were significantly shorter in the HoLEP group. Both groups showed a statistically significant improvement in functional performance at three months post-surgery. Complications in the HoLEP and EVS adenomectomy group occurred in 18 (20%) and 23 (25.55%) patients, respectively (p>0.99). CONCLUSION: The two methods mentioned above are widely used in the treatment of prostate adenoma. However, holmium laser enucleation of the prostate shows similar short-term functional results and complication rates compared with EVS adenomectomy for prostate adenomas greater than 100 cm3. The patients of the HoLEP group had better results regarding the duration of catheterization and length of postoperative hospital stay. Therefore, laser enucleation is the preferred surgical modality for prostate adenomas greater than 100 cm3.
[Mh] Termos MeSH primário: Terapia a Laser/métodos
Tempo de Internação
Próstata/cirurgia
Hiperplasia Prostática/cirurgia
Cirurgia Vídeoassistida/métodos
[Mh] Termos MeSH secundário: Idoso
Seres Humanos
Masculino
Próstata/patologia
Hiperplasia Prostática/patologia
[Pt] Tipo de publicação:CLINICAL TRIAL; COMPARATIVE STUDY; JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180130
[St] Status:MEDLINE


  3 / 19186 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29376600
[Au] Autor:Biktimirov RG; Martov AG; Biktimirov TR; Kaputovskii AA
[Ad] Endereço:Federal Clinical Center for High Medical Technologies FMBA of Russia, Moscow Region, Khimki, Russia.
[Ti] Título:[The role of extraperitoneoscopic adenomectomy in the management of benign prostatic hyperplasia greater than 80 cm3].
[So] Source:Urologiia;(6):76-81, 2017 Dec.
[Is] ISSN:1728-2985
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:INTRODUCTION: The current standard of surgery for benign prostatic hyperplasia (BPH) greater than 80 cm3 includes open adenomectomy and holmium enucleation. Transurethral resection and laser vaporization are second line interventions, while the role of laparoscopic extraperitoneal adenomectomy is not fully understood. AIM: To evaluate the role of laparoscopic technique as a surgical modality for BPH greater than 80 cm3. MATERIALS AND METHODS: This study retrospectively evaluated the results of 79 patients (mean age 68 years) who underwent transcapsular extraperitoneoscopic adenomectomy from 2011 to 2016. RESULTS: The mean operative time was 206 (100-450) min; the prostate volume was 134 (80-300) cm3, blood loss was 256 (30-1200) ml. The I-PSS score after surgery decreased by an average of 18.3 points, the maximum urinary flow rate increased by 12 ml/s, the residual urine volume reduced from 147 to 28 ml. 35 (44%) patients underwent simultaneous operations (inguinal hernioplasty, cystolithotomy, etc.). There was one intraoperative complication, and 10 (12.6%) patients had postoperative complications. There were no conversions to open surgery. Incidental prostate cancer was detected in one patient. None of the patients required repeat surgery for infravesical obstruction. CONCLUSION: Extraperitoneoscopic adenomectomy is efficient, safe and reproducible surgical modality able to take the place of open surgery. There is a need for an evidence base to support the optimal choice between various minimally invasive techniques. Currently, laparoscopic procedure is more justified in patients with concomitant diseases, which can be simultaneously corrected.
[Mh] Termos MeSH primário: Laparoscopia/métodos
Hiperplasia Prostática/cirurgia
Procedimentos Cirúrgicos Urológicos Masculinos/métodos
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Seres Humanos
Masculino
Meia-Idade
Hiperplasia Prostática/diagnóstico por imagem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180130
[St] Status:MEDLINE


  4 / 19186 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29376596
[Au] Autor:Krivoborodov GG; Efremov NS; Bolotov AD
[Ad] Endereço:Department of Urology and Andrology, Medical Faculty of N.I. Pirogov RNRMU of Minzdrav of Russia, Moscow, Russia.
[Ti] Título:[Transabdominal and transrectal ultrasound assessment of intravesical prostatic protrusion].
[So] Source:Urologiia;(6):55-58, 2017 Dec.
[Is] ISSN:1728-2985
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:RELEVANCE: Benign prostatic hyperplasia (BPH) is one of the most common urological diseases among men. Despite the noticeable positive effects of pharmacotherapy on the quality of urination in BPH, the presence of an intravesical obstruction (IVO) leads to discontinuation of conservative treatment in favor of surgical interventions. One of the features of prostate enlargement is the degree of its intravesical growth (intravascular prostatic protrusion, IPP). According to some studies, IPP value of 10 mm or more is indicative of IVO in virtually all men. AIM: To compare transabdominal and transrectal ultrasound measurement of IPP in men with BPH. MATERIALS AND METHODS: The study comprised 108 men aged 69+/-10 years (43 to 93 years) with lower urinary tract symptoms and BPH. Patients underwent a standard urological examination. The shape of the prostate, prostate volume and the measurements of the IPP were assessed using transabdominal and transrectal ultrasound. RESULTS: The IPP measurements obtained using transabdominal and transrectal ultrasound were 9.8+/-5.7 mm (1.1 to 28 mm) and 9.3+/-5.3 mm (0.5 to 26 mm), respectively. The IPP measurements evaluated by transabdominal and transrectal ultrasound were found comparable regardless of the prostate volume. CONCLUSION: Similar results in assessing PPI by both ultrasound modalities allow them to be used equally effectively.
[Mh] Termos MeSH primário: Hiperplasia Prostática/diagnóstico por imagem
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Seres Humanos
Masculino
Meia-Idade
Ultrassonografia/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180130
[St] Status:MEDLINE


  5 / 19186 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29351556
[Au] Autor:Li J; Tian Y; Guo S; Gu H; Yuan Q; Xie X
[Ad] Endereço:Chinese Academy of Sciences Key Laboratory of Receptor Research, National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
[Ti] Título:Testosterone-induced benign prostatic hyperplasia rat and dog as facile models to assess drugs targeting lower urinary tract symptoms.
[So] Source:PLoS One;13(1):e0191469, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Benign prostatic hyperplasia (BPH) is an age-related disease, affecting a majority of elderly men worldwide. Medical management of BPH is an alternative to surgical treatment of this disease. Currently, α1-adrenergic receptor (α1-AR) antagonists are among the first line drugs to treat BPH by reducing the tension of urinary track and thus the obstructive symptoms in voiding. In drug development, old male dogs with spontaneous BPH are considered the golden standard of the animal models. However, old dogs (>6 years) are expensive and not all old dogs develop BPH. So it is necessary to develop more accessible animal models for drug efficacy evaluation. Here we describe the development of testosterone-induced BPH models in both rats and young adult dogs and their applications in the in vivo evaluation of α1-AR antagonist. The BPH rats and dogs induced by chronic testosterone treatment have significantly increased micturition frequency and reduced mean voided volume, very similar to the clinical symptoms of BPH patients. Silodosin, an α1-AR antagonist, significantly reduces the urinary frequency and increases the voided volume in BPH model animals in a dose-dependent manner. The results demonstrate that testosterone-induced BPH rat and dog models might provide a more efficient way to evaluate micturition behavior in anti-BPH drug studies.
[Mh] Termos MeSH primário: Sintomas do Trato Urinário Inferior/tratamento farmacológico
Hiperplasia Prostática/induzido quimicamente
Testosterona/toxicidade
[Mh] Termos MeSH secundário: Antagonistas de Receptores Adrenérgicos alfa 1/uso terapêutico
Idoso
Animais
Modelos Animais de Doenças
Cães
Avaliação Pré-Clínica de Medicamentos
Feminino
Seres Humanos
Indóis/uso terapêutico
Sintomas do Trato Urinário Inferior/etiologia
Sintomas do Trato Urinário Inferior/fisiopatologia
Masculino
Hiperplasia Prostática/complicações
Hiperplasia Prostática/patologia
Ratos
Ratos Sprague-Dawley
Testosterona/administração & dosagem
Micção/efeitos dos fármacos
Agentes Urológicos/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Adrenergic alpha-1 Receptor Antagonists); 0 (Indoles); 0 (Urological Agents); 3XMK78S47O (Testosterone); CUZ39LUY82 (silodosin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180120
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191469


  6 / 19186 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29382326
[Au] Autor:Chen X; Wu RZ; Zhu YQ; Ren ZM; Tong YL; Yang F; Dai GH
[Ad] Endereço:Institute of Basic Medicine, Zhejiang Academy of Traditional Chinese Medicine, No. 132, Tianmushan Road, Xihu District, Hangzhou, Zhejiang, China.
[Ti] Título:Study on the inhibition of Mfn1 by plant-derived miR5338 mediating the treatment of BPH with rape bee pollen.
[So] Source:BMC Complement Altern Med;18(1):38, 2018 Jan 30.
[Is] ISSN:1472-6882
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Recent studies have found that plant derived microRNA can cross-kingdom regulate the expression of genes in humans and other mammals, thereby resisting diseases. Can exogenous miRNAs cross the blood-prostate barrier and entry prostate then participate in prostate disease treatment? METHODS: Using HiSeq sequencing and RT-qPCR technology, we detected plant miRNAs that enriched in the prostates of rats among the normal group, BPH model group and rape bee pollen group. To forecast the functions of these miRNAs, the psRobot software and TargetFinder software were used to predict their candidate target genes in rat genome. The qRT-PCR technology was used to validate the expression of candidate target genes. RESULTS: Plant miR5338 was enriched in the posterior lobes of prostate gland of rats fed with rape bee pollen, which was accompanied by the improvement of BPH. Among the predicted target genes of miR5338, Mfn1 was significantly lower in posterior lobes of prostates of rats in the rape bee pollen group than control groups. Further experiments suggested that Mfn1 was highly related to BPH. CONCLUSIONS: These results suggesting that plant-derived miR5338 may involve in treatment of rat BPH through inhibiting Mfn1 in prostate. These results will provide more evidence for plant miRNAs cross-kingdom regulation of animal gene, and will provide preliminary theoretical and experimental basis for development of rape bee pollen into innovative health care product or medicine for the treatment of BPH.
[Mh] Termos MeSH primário: Proteínas de Membrana/antagonistas & inibidores
MicroRNAs/farmacologia
Proteínas Mitocondriais/antagonistas & inibidores
Pólen
Próstata/efeitos dos fármacos
Hiperplasia Prostática/metabolismo
RNA de Plantas/farmacologia
[Mh] Termos MeSH secundário: Animais
Abelhas
Peso Corporal/efeitos dos fármacos
Masculino
Proteínas de Membrana/metabolismo
Proteínas Mitocondriais/metabolismo
Tamanho do Órgão/efeitos dos fármacos
RNA de Plantas/farmacocinética
Ratos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Membrane Proteins); 0 (MicroRNAs); 0 (Mitochondrial Proteins); 0 (RNA, Plant); 0 (mitofusin 1 protein, rat)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1186/s12906-018-2107-y


  7 / 19186 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28453908
[Au] Autor:Corona G; Tirabassi G; Santi D; Maseroli E; Gacci M; Dicuio M; Sforza A; Mannucci E; Maggi M
[Ad] Endereço:Endocrinology Unit, Maggiore-Bellaria Hospital, Medical Department, Azienda-Usl Bologna, Bologna, Italy.
[Ti] Título:Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.
[So] Source:Andrology;5(4):671-678, 2017 07.
[Is] ISSN:2047-2927
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Despite their efficacy in the treatment of benign prostatic hyperplasia, the popularity of inhibitors of 5α-reductase (5ARIs) is limited by their association with adverse sexual side effects. The aim of this study was to review and meta-analyze currently available randomized clinical trials evaluating the rate of sexual side effects in men treated with 5ARIs. An extensive Medline Embase and Cochrane search was performed including the following words: 'finasteride', 'dutasteride', 'benign prostatic hyperplasia'. Only placebo-controlled randomized clinical trials evaluating the effect of 5ARI in subjects with benign prostatic hyperplasia were considered. Of 383 retrieved articles, 17 were included in this study. Randomized clinical trials enrolled 24,463 in the active and 22,270 patients in the placebo arms, respectively, with a mean follow-up of 99 weeks and mean age of 64.0 years. No difference was observed between trials using finasteride or dutasteride as the active arm considering age, trial duration, prostate volume or International Prostatic Symptoms Score at enrollment. Overall, 5ARIs determined an increased risk of hypoactive sexual desire [OR = 1.54 (1.29; 1.82); p < 0.0001] and erectile dysfunction [OR = 1.47 (1.29; 1.68); p < 0.0001]. No difference between finasteride and dutasteride regarding the risk of hypoactive sexual desire and erectile dysfunction was observed. Meta-regression analysis showed that the risk of hypoactive sexual desire and erectile dysfunction was higher in subjects with lower Q at enrollment and decreased as a function of trial follow-up. Conversely, no effect of age, low urinary tract symptom or prostate volume at enrollment as well as Q at end-point was observed. In conclusion, present data show that the use of 5ARI significantly increases the risk of erectile dysfunction and hypoactive sexual desire in subjects with benign prostatic hyperplasia. Patients should be adequately informed before 5ARIs are prescribed.
[Mh] Termos MeSH primário: Inibidores de 5-alfa Redutase/efeitos adversos
Dutasterida/efeitos adversos
Disfunção Erétil/induzido quimicamente
Finasterida/efeitos adversos
Hiperplasia Prostática/tratamento farmacológico
Disfunções Sexuais Psicogênicas/induzido quimicamente
[Mh] Termos MeSH secundário: Adulto
Idoso
Disfunção Erétil/fisiopatologia
Seres Humanos
Libido/efeitos dos fármacos
Masculino
Meia-Idade
Ereção Peniana/efeitos dos fármacos
Hiperplasia Prostática/enzimologia
Ensaios Clínicos Controlados Aleatórios como Assunto
Fatores de Risco
Comportamento Sexual/efeitos dos fármacos
Disfunções Sexuais Psicogênicas/fisiopatologia
Disfunções Sexuais Psicogênicas/psicologia
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (5-alpha Reductase Inhibitors); 57GNO57U7G (Finasteride); O0J6XJN02I (Dutasteride)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1111/andr.12353


  8 / 19186 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28466017
[Au] Autor:Xu N; Chen SH; Xue XY; Wei Y; Zheng QS; Li XD; Huang JB; Cai H; Sun XL; Lin YZ
[Ad] Endereço:Department of Urology, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China.
[Ti] Título:Older Age and Larger Prostate Volume Are Associated with Stress Urinary Incontinence after Plasmakinetic Enucleation of the Prostate.
[So] Source:Biomed Res Int;2017:6923290, 2017.
[Is] ISSN:2314-6141
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:To investigate the factors associated with the occurrence of and recovery from stress urinary incontinence (SUI) after plasmakinetic enucleation of the prostate (PKEP). This retrospective study enrolled 1,288 patients with benign prostatic hyperplasia treated with plasmakinetic enucleation from January 2008 to January 2015, collecting demographics and clinical parameters. SUI was defined as a patient complaint of involuntary urine leak, including stress or mixed urinary incontinence. Logistic regression analysis was used to investigate the factors associated with the occurrence of SUI. SUI after PKEP occurred in 80 of 1,288 patients (6.2%), 73 of whom (91.3%) recovered within 3 months and 78 of whom (97.5%) recovered within 6 months. In multivariate regression analysis of factors that were significant in univariate analysis, the factors that were significantly associated with postoperative SUI were age ≥ 70 years (odds ratio [OR] = 9.239; 95% confidence interval [CI] = 4.616-18.495; < 0.001) and prostate volume on transrectal ultrasound ≥ 90 mL (OR = 15.390; 95% CI = 8.077-29.326; < 0.001). SUI occurred in 6.2% patients after PKEP and was associated with older age and larger prostate volume. We suggest that age and prostate volume be considered in preoperative candidate selection before PKEP to reduce the occurrence of postoperative SUI.
[Mh] Termos MeSH primário: Próstata/patologia
Hiperplasia Prostática/patologia
Incontinência Urinária por Estresse/patologia
[Mh] Termos MeSH secundário: Fatores Etários
Idoso
Idoso de 80 Anos ou mais
Seres Humanos
Masculino
Meia-Idade
Próstata/cirurgia
Hiperplasia Prostática/cirurgia
Estudos Retrospectivos
Ressecção Transuretral da Próstata/métodos
Incontinência Urinária por Estresse/cirurgia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.1155/2017/6923290


  9 / 19186 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29406059
[Au] Autor:Alawamlh OAH; Goueli R; Lee RK
[Ad] Endereço:Department of Urology, Weill Medical College of Cornell University, James Buchanan Brady Foundation, New York, NY, USA.
[Ti] Título:Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia, and Urinary Retention.
[So] Source:Med Clin North Am;102(2):301-311, 2018 Mar.
[Is] ISSN:1557-9859
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Lower urinary tract symptoms (LUTS) consist of a common set of urologic symptoms that can affect the elderly. The prevalence of LUTS is expected to rise owing to the continued increase of numbers of the elderly. Although benign prostatic hyperplasia is considered a common cause of LUTS, the broader potential causes of LUTS are myriad. A wide range of diagnostic modalities and treatments are available to manage patients with LUTS and their utilization should not be limited to the urologist.
[Mh] Termos MeSH primário: Sintomas do Trato Urinário Inferior
Hiperplasia Prostática
Retenção Urinária
[Mh] Termos MeSH secundário: Seres Humanos
Sintomas do Trato Urinário Inferior/etiologia
Masculino
Hiperplasia Prostática/complicações
Retenção Urinária/etiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180207
[St] Status:MEDLINE


  10 / 19186 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28454190
[Au] Autor:Piwowarski JP; Bobrowska-Korczak B; Stanislawska I; Bielecki W; Wrzesien R; Granica S; Krupa K; Kiss AK
[Ad] Endereço:Department of Pharmacognosy and Molecular Basis of Phytotherapy, Medical University of Warsaw, Poland.
[Ti] Título:Evaluation of the Effect of Epilobium angustifolium Aqueous Extract on LNCaP Cell Proliferation in In Vitro and In Vivo Models.
[So] Source:Planta Med;83(14-15):1159-1168, 2017 Oct.
[Is] ISSN:1439-0221
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:sp. are commonly used in traditional medicine in the treatment of early stages of benign prostatic hyperplasia and inflammation. It is suggested that a dominating constituent, oenothein B, is responsible for the extracts therapeutic effects. Several bioactivities were established for extracts and oenothein B in various models, but due to the questionable bioavailability of this dimeric macrocyclic ellagitannin, their significance in the effects remains unresolved. We have thus focused our attention on a complex comparative investigation of the and activities of phytochemically characterized aqueous extract and oenothein B on prostate cancer cells proliferation.Incubation of different cell lines with aqueous extract resulted in a significant reduction of proliferation of PZ-HPV-7 and LNCaP cells, which was partly associated with antiandrogenic activity. These effects were fully congruent with oenothein B, examined in parallel. Oral supplementation of rats implanted with LNCaP cells with aqueous extract 50-200 mg/kg b. w. resulted in a reduction of the occurrence of prostatic adenoma up to 13 %. Oenothein B was not detected in the urine and feces of the aqueous extract-treated group, however, conjugates of nasutins gut microbiota metabolites of ellagitannins were detected in the urine, while in human volunteers supplemented with tea, only urolithin conjugates were present.Despite observing significant and consistent effects and , we were unable to point out unequivocally the factors contributing to the observed aqueous extract activity, facing the problems of an unknown metabolic fate of oenothein B and interspecies differences in aqueous extract gut microbiota metabolism.
[Mh] Termos MeSH primário: Epilobium/química
Taninos Hidrolisáveis/farmacologia
Extratos Vegetais/farmacologia
Hiperplasia Prostática/tratamento farmacológico
Neoplasias da Próstata/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Linhagem Celular Tumoral
Seres Humanos
Inflamação/tratamento farmacológico
Masculino
Medicina Tradicional
Extratos Vegetais/química
Extratos Vegetais/isolamento & purificação
Polifenóis/farmacologia
Ratos
Água
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hydrolyzable Tannins); 0 (Plant Extracts); 0 (Polyphenols); 0 (ellagitannin); 059QF0KO0R (Water); 104987-36-2 (oenothein B)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180201
[Lr] Data última revisão:
180201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1055/s-0043-109372



página 1 de 1919 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde